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Abstract
B cells have the unique property to somatically alter their immunoglobulin (IG) genes by V(D)J recombination, somatic
hypermutation (SHM) and class-switch recombination (CSR). Aberrant targeting of these mechanisms is implicated in
lymphomagenesis, but the mutational processes are poorly understood. By performing whole genome and transcriptome
sequencing of 181 germinal center derived B-cell lymphomas (gcBCL) we identified distinct mutational signatures linked to
SHM and CSR. We show that not only SHM, but presumably also CSR causes off-target mutations in non-IG genes.
Kataegis clusters with high mutational density mainly affected early replicating regions and were enriched for SHM- and
CSR-mediated off-target mutations. Moreover, they often co-occurred in loci physically interacting in the nucleus,
suggesting that mutation hotspots promote increased mutation targeting of spatially co-localized loci (termed hypermutation
by proxy). Only around 1% of somatic small variants were in protein coding sequences, but in about half of the driver genes,
a contribution of B-cell specific mutational processes to their mutations was found. The B-cell-specific mutational processes
contribute to both lymphoma initiation and intratumoral heterogeneity. Overall, we demonstrate that mutational processes
involved in the development of gcBCL are more complex than previously appreciated, and that B cell-specific mutational
processes contribute via diverse mechanisms to lymphomagenesis.
Introduction
B-cell neoplasms encompass more than 80% of lymphoid
malignancies worldwide [1]. The most common types of
mature B-cell neoplasms are diffuse large B-cell lymphoma
(DLBCL) and follicular lymphoma (FL), accounting for
more than 50% of adult B-cell lymphomas. Both are
germinal center (GC)-derived B-cell lymphomas (gcBCL).
While DLBCL is a heterogeneous group of aggressive
lymphomas, FL is indolent but can progress to DLBCL.
DLBCL comprises two subgroups, defined by gene
expression as germinal center B-cell like (GCB) and acti-
vated B-cell like (ABC), with some cases left unclassified
[2, 3]. More recently, new subdivisions of DLBCL based on
the patterns of mutated genes were proposed [4–7].
Lymphocytes are the only somatic cells in humans which
actively alter their genomes in their physiological matura-
tion program. Early in B-cell development, V(D)J recom-
bination rearranges immunoglobulin (IG) genes to generate
initial antigen receptor diversity. In response to T cell-
dependent antigens, B cells undergo rapid proliferation in
the GC [8]. Concurrently, mutations are introduced in the
IG variable region genes which encode the antigen binding
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sites in a process called somatic hypermutation (SHM) to
further diversify the IG repertoire [8]. Moreover, activated
B cells can change the antibody isotype via class-switch
recombination (CSR), which involves excision of a DNA
fragment [9].
Both SHM and CSR are initiated by activation-induced
cytidine deaminase (AID), which deaminates cytosine (C)
to uracil (U) [10]. SHM introduces single nucleotide var-
iants (SNVs) in the IG variable regions due to diverse error-
prone DNA repair processes activated in response to AID
activity. CSR, in contrast, is focused on the generation of
DNA strand breaks into switch regions located 5’ of the IG
heavy chain constant region genes (IG-switch), involving
distinct factors [9].
Physiologic activity of AID is restricted to the IG loci
and at much lower frequency also to a few non-IG off-
targets (e.g., BCL6) [11]. However, AID activity also causes
chromosomal translocations, and in particular in DLBCL,
numerous additional genes are aberrantly targeted by SHM
[12–14]. AID-mediated mutations have hence been impli-
cated as key events in B-cell lymphomagenesis [14, 15].
Indeed, most gcBCLs exhibit oncogene translocations and
recurrent targeting of B cell-specific genes by mutations
ascribed to aberrant SHM [13, 14, 16]. However, a com-
prehensive understanding of the mutational mechanisms
and genome-wide patterns in gcBCL is missing. We ana-
lyzed whole genome and transcriptome sequencing data of
181 and 176 gcBCL, respectively, in order to understand
the origin and implications of somatic mutations in gcBCL.
We dissect the mutational mechanisms shaping their gen-
omes and use a comprehensive approach to elucidate how
these mutate the driver genes.
Material and methods
Sample selection, genomic and transcriptomic sequencing
and bioinformatic evaluations followed the guildelines of
the International Cancer Genome Consortium (ICGC) [17–
20]. For details see Supplementary Methods.
Results
Mutational landscape
We performed whole genome sequencing of 181 pre-
treatment lymphoma samples from adult patients, and 179
matching nontumor tissues using inclusion criteria described
in the “Methods” section (Supplementary Table S1A). The
cohort encompasses 86 FL, 17 FL/DLBCL (As FL/DLBCL
cases were classified which either were composite of two
compartments or in which histopathologic reviews did not
yield an unambgious differentiation between both), 76
DLBCL, 1 unspecified B-cell lymphoma, and 1 lymphoma
with features intermediate between DLBCL and Burkitt
lymphoma (BL) (Supplementary Table S1B). Tran-
scriptomes were obtained from 176 of the cases and used to
molecularly classify them, adapting published indices [2].
We assigned 171 cases to the nonmolecular BL group, two to
the molecular BL group, and three showed an intermediate
profile. To increase statistical power for detecting common
mutational mechanisms of B cells, these gcBCL subgroups
were analyzed together in a subset of the analyses.
Whole genome sequencing data were obtained with a
median coverage of 36.4 (range 24.1–56.4) and 37.0 (range
26.4–77.5) in tumors and controls, respectively, and inter-
rogated for somatic mutations including SNVs, insertions and
deletions (indels), structural variants (SVs), and copy number
aberrations (CNAs). We identified a median of 8186 (range
1,236–138,620; subgroup specific median DLBCL: 12,943,
FL: 5,933, FL/DLBCL: 13,381) somatic small variants
(SNVs and indels) per tumor (Supplementary Fig. S1A).
A median of 55 SVs (range 2–1317; inversions: 9, dele-
tions: 7, duplications: 26, translocations: 6) was detected per
case. Most SVs were detected in FL/DLBCL (median: 100)
and DLBCL (77). The number in FLs was considerably
lower (35), indicating higher genomic instability in DLBCL
and FL/DLBCL than in FL. The number of SVs correlated
with the number of small mutations (Supplementary Fig.
S1B). Regarding CNAs (deleted or gained genomic seg-
ments >1Mb) DLBCLs (median 9 gains/5 losses) and FL/
DLBCL (8/5) showed more CNAs than FLs (2/3), matching
previous studies (Supplementary Fig. S1D, E) [21–23].
SNVs exhibited a highly uneven distribution across the
genome (Fig. 1A, Supplementary Fig. S2A). Cohort-wide
analysis of SNV density in 1Mb windows revealed a cor-
relation between SNV density and replication timing [24],
with higher SNV density in late replicating regions
(Fig. 1B), as described [25]. However, some early repli-
cating regions showed a very high mutation density. An
increased fraction of SNVs in those windows affected the
DGYW sequence motif, a preferred SHM target [26]. Many
targets of physiological and aberrant SHM are located in
these windows [13], e.g., BCL2 and PAX5 (Fig. 1B).
Since the cohort-wide analysis masks inter-individual
differences, we analyzed fluctuations in SNV density in
individual genomes, excluding two cases without matched
normal tissue. We identified 4538 clusters of very high
mutation density (termed kataegis clusters) [27, 28] in 219
lymphoma genomes (consisting of 179 genomes from this
study plus 39 pediatric BLs [17] and one adult BL, Sup-
plementary Table S2), using a definition of a maximal
intermutation distance of 1000 bp and a minimum of five
mutations per cluster. Almost half of these (2,145, 47.3%)
were recurrent in at least three patients and affected 166
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genomic regions, which we term kataegis regions (Fig. 2 and
Supplementary Fig. S3; upon omission of four hypermutated
DLBCL cases, defined by more than two standard deviations
above mean SNV mutational load, cf. Supplementary
Information, 157 kataegis regions were identified—the dif-
ference of nine recurrent kataegis clusters contains exclu-
sively known and established targets of SHM). 91 kataegis
regions were located outside of IG loci. DLBCLs and FL/
DLBCLs displayed higher median numbers of kataegis
clusters, affected kataegis regions both inside the IG loci,
outside the IG loci and overall as well as higher counts of
SNVs in kataegis clusters (Supplementary Fig. S2B and
Supplementary Table S3A). Among DLBCLs, GCB-
DLBCL had higher mutational load (medians for ABC-
DLBCL: 8,978 and GCB-DLBCL: 12,478), higher median
numbers of kataegis clusters and affected kataegis regions,
higher counts of SNVs in kataegis clusters and regions than
ABC-DLBCL (Supplementary Fig. S2D and Supplementary
Table S3B, C).
Beyond kataegis clusters with high mutation density, we
also found regions with an intermediate mutation density,
which we term psichales (ψιχάλεϛ, ancient greek for
“drizzling rain”; Supplementary Figs. S2B and S4).
Kataegis and psichales exhibit a remarkably different dis-
tribution over the genome, with kataegis clusters being
bound to early replicating regions [24], whereas psichales is
characteristic of late replicating regions (Fig. 1C, Supple-
mentary Fig. S4). This suggests that psichales corresponds
Fig. 1 Mutation density and replication timing. A Rainfall plots of
three samples including one FL (uppermost track) and two DLBCLs
(second and third tracks from the top). For every track, the x-axis
displays the genomic coordinate and the y-axis the log-scaled inter-
mutation distance. Clusters of hypermutation (kataegis clusters) can be
identified as “rainfalls” reaching very low intermutation distance. The
IG loci are highlighted by red vertical lines and red labels, some
hallmark genes involved in lymphomagenesis are highlighted by black
vertical lines and black labels. B–D Correlation with replication tim-
ing. Replication timing is indicated as RepliSeq score of the respective
genomic region as determined in [24] (see “Methods” for details).
B Scatterplot of replication timing vs. mutation density, showing an
inverse relationship between these two quantities. Outliers in this plot,
i.e., exceptions from the inverse relationship, are typical targets of
SHM in gcBCL. C Boxplot and violin plot of replication time vs.
cluster category, demonstrating that kataegis is significantly enriched
in early replicating regions (p < 10−16) and psichales in late replicating
regions (p < 10−16) of the genome. D Rewiring of replication timing:
kataegis regions are located in regions of the genome which are earlier
replicating in lymphoblastoid cell lines (y-axis) than in other cell lines
(HeLa-S3 (cervical adenocarcinoma), HUVEC (umbilical vein endo-
thelial cells), K562 (chronic myelogenous leukemia in blast crisis),
NHEK (epidermal keratinocytes), MCF-7 (mammary gland, adeno-
carcinoma), IMR-90 (fetal lung fibroblasts), and HepG2 (hepatocel-
lular carcinoma) (x-axis). The light blue color in the background
indicates the 95% quantile, the dark blue one the 68% quantile
(respective fractions of all SNVs are situated on the colored areas).
Regions with a difference in RepliSeq score > 3 are annotated by the
closest gene.
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to the known increased mutation rate in late replicating
heterochromatic regions [25, 29] (Supplementary Fig. S5,
Supplementary Table S4) caused by differential DNA
mismatch repair [30], while kataegis in gcBCL is caused by
focal hypermutation of active genomic regions. Replication
timing profiles differ between cell lines originating from
different tissues [24]. Interestingly, kataegis clusters were
enriched in genomic regions where lymphoblastoid cell
lines show earlier replication than nonlymphoid cell lines
(Fig. 1D). Similar to gcBCL, lymphoblastoid cell lines
represent immortalized mature B cells and share with
DLBCL a mature B-cell phenotype, strong proliferation,
and expression of numerous B cell-typical genes. The
enrichment of kataegis clusters in genomic regions where
lymphoblastoid cell lines show earlier replication than the
other cell lines shows that genomic regions early replicating
specifically in B cells are particularly prone to become
hypermutated.
Aberrant SHM and aberrant CSR cause clusters of
hypermutation
To understand the mutational mechanisms introducing the
high number of kataegis clusters in gcBCL genomes we
Fig. 2 Analysis of mutation density dissects aberrant targeting of
SHM and CSR. A Patterns of nucleotide exchanges in their triplet
contexts as extracted cohort wide in the switch regions (upper track) and
the regions containing V, D and J genes (middle track). These patterns
are not mutational signatures, instead they correspond to visualizations
of mutational catalogs. Scales on the y-axes in the different tracks are
not fixed, instead a horizontal line is inserted at 5% for rough orientation
and comparison. B Clustering of the kataegis clusters according to their
contributions from CSR-like and SHM-like mutational processes with
contributions of SHM-like and CSR-like as axes. Assessment of the
contributions of these two mechanisms to all kataegis clusters was
performed by non-negative least squares and subsequent unsupervised
k-means clustering (k= 3). Kataegis clusters dominated by a CSR-like
pattern are colored in orange, clusters dominated by a SHM-like pattern
are colored in green and clusters dominated by neither pattern (other)
are colored in purple. C kataegis clusters and kataegis regions displayed
as oncoprint. The x-axis encodes samples, the y-axis the kataegis
regions, which are ordered by recurrency of affection (≥3%, note that for
a better overview, the well established kataegis regions in the IG, BCL2
and BCL6 loci are excluded from the inferred oncoprint-like ordering of
the samples and only shown for completeness in the lowest five rows).
The oncoprint carries four layers of annotation (normalized horizontal
stacked barplots): (i) the fractions of the different kataegis cluster
categories (SHM-like = green, CSR-like = orange and other = purple);
(ii) the mean distance to the closest TSS in bp; (iii) the fraction of
variants overlapping exons (black); and (iv) the fractions of chromatin
states from GC B cells annotated to the variants in the respective
kataegis regions.
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analyzed the SNV profiles at the IG loci, the physiological
targets of B cell-specific mutagenesis. We derived con-
sensus coordinates of the IG switch regions (Supplemen-
tary Figs. S6 and S7, Supplementary Information), and
then extracted SNVs in the switch regions and IG V
regions (IG-VDJ). Profiles of nucleotide exchanges in their
triplet context (corresponding to the concept of a muta-
tional catalog [27]) differed strongly between SNVs
located in IG-switch, IG-VDJ and the overall mutational
catalog (Fig. 2A). We defined the SNV profile derived
from IG-switch as CSR profile and from IG-VDJ as SHM
profile. The CSR profile consists almost exclusively of
four triplets corresponding to a DGC/GCH motif (mutation
hotspot underlined), and is therefore much more focused
than the previously described RGYW/WRCY or DGYW/
WRCH motifs. In contrast, the SHM profile shows a much
more diverse nucleotide exchange pattern. These patterns
are consistent with SNVs introduced by CSR being mainly
the result of focused repair of AID-mediated C to U dea-
mination, while SHM includes strong modulation by error-
prone DNA repair pathways.
We hypothesized that kataegis outside the IG loci may
be due to aberrant targeting of either SHM or CSR.
Assessment of the contributions of these two mechanisms
to all kataegis clusters revealed three classes of kataegis
clusters (Fig. 2B): one with predominant contributions of
SHM (n= 2,323, 51.2%), one with predominant con-
tributions of CSR (n= 428, 9.4%) and one with low
contributions of SHM and CSR (n= 1,787, 39.4%). This
classification persisted when clustering only the kataegis
clusters located outside IG loci with 97.6% identical
assignments (Supplementary Fig. S2F). Some kataegis-
regions showed strong enrichment of SHM-like kataegis
clusters like those in proximity of RHOH and DTX1,
whereas others, like CIITA, PAX5 or CD74, had mainly
contributions from CSR-like clusters (Fig. 2C). This sug-
gests that beyond aberrant SHM, the mutational landscape
of gcBCLs is also shaped by aberrant targeting of the CSR
machinery.
Due to the fact that FL showed less kataegis clusters in
total than DLBCL and FL/DLBCL, absolute numbers of
CSR-like, SHM-like and “other” kataegis clusters (Sup-
plementary Fig. S8 A, E, I) and SNVs (Supplementary Fig.
S2C, items 1, 2) were lower in FL. However, when asses-
sing the relative fraction of the respective classes of kataegis
clusters among all kataegis clusters, remarkable differences
were observed: while these fractions showed a trend
towards lower values in FL than in DLBCL and FL-
DLBCL for CSR-like (Supplementary Fig. S8 B, J) kataegis
clusters and SNVs (Supplementary Fig. S2C, items 3–4),
they were higher for SHM-like kataegis clusters (Supple-
mentary Fig. S8F) and SNVs (Supplementary Fig. S2C,
item 5).
Hypermutation by proxy
SHM typically introduces mutations within a window of
roughly 2.5 kb 3’ of the transcription start site (TSS). 2581/
4538 (56.9%) of all kataegis clusters and 2142/2460
(87.1%) of the recurrent kataegis clusters fulfilled these
criteria. However, 1056 (23.3%) of all and 39 (1.6%) of the
recurrent kataegis clusters were more than 20 kb away from
the next TSS (Supplementary Information). The SHM-like
and CSR-like profiles were depleted among these so called
“TSS-distant” kataegis clusters (Supplementary Table S5A,
H and J). We annotated chromatin states computed from
ChIP-Seq of three GC B-cell samples [31, 32] to the
kataegis clusters (Fig. 2C). As expected, both SHM-like
(1236/2321, 53%) and CSR-like clusters (317/427, 74%)
were primarily located in promoters (Supplementary
Table S5B). In contrast, most kataegis clusters of type “non-
CSR/non-SHM-like” mapped to heterochromatin (917/
1784= 51%).
As there is indication that AID off-target activity is
linked to topologically associated chromatin domains in the
interphase nuclei of B cells [33], we hypothesized that TSS-
distant kataegis hypermutation is caused by secondary tar-
geting of the hypermutation machinery while primarily
affecting aberrant hypermutation of target regions in spatial
proximity. Hence, we systematically analyzed co-
occurrence of kataegis regions (Fig. 3A). Per sample,
hypermutation in certain kataegis-regions (termed object
regions) occurred only if another kataegis-region (subject
region) is affected (Fig. 3B, Supplementary Figs. S9, S10A,
and S10F, Supplementary Table S6). Counting subject and
object regions together, 77 kataegis regions outside and 16
inside the IG loci were involved in such relationships.
Restricting the analysis to the 192 identified conditional co-
occurrence relationships outside IG loci, 167 were inter-
chromosomal, 10 were long-range intra-chromosomal
(defined by a distance > 1Mbp), and 15 were short-range
intra-chromosomal effects. This suggests that the subject
regions are primary targets of hypermutation, while the
object regions may be exposed to the hypermutation
machinery due to spatial co-localization. Indeed, the frac-
tion of TSS-far kataegis regions was higher among the
objects than among the subjects, regardless of whether IG
loci are taken into consideration or not (Supplementary
Table S7A–C). We introduced the term hypermutation by
proxy (HbP) to describe such a relationship. Examples for
subject regions include BCL6 (Supplementary Fig.
S10A–E) and PAX5 (Supplementary Fig. S10F–I). Both
BCL6 and PAX5 are located in gene clusters, and the HbP
effect leads to secondary targeting of one or several object
regions in genes within these clusters. Several objects of
PAX5 overlap with the PAX5 enhancer described as recur-
rently mutated in chronic lymphocytic leukemia [34],
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suggesting that HbP may cause enhancer hypermutation.
Another example affects S1PR2 as subject and DNMT1 as
object (Fig. 3B–D; Supplementary Information).
In order to relate the concept of HbP to actual spatial
colocalization in the nucleus, we investigated the con-
cordance between the HbP relationships and published
chromatin conformation data [35, 36] (Supplementary
Table S8). Indeed, many intrachromosomal HbP relation-
ships were reflected by strong interaction signals in the
chromatin conformation data, such as gene clusters around
PAX5 and BCL6. However, inter-chromosomal HbP rela-
tionships could not be confirmed by the conformation data,
probably because very long-range intrachromosomal and
interchromosmal interactions are typically less reliably
identified than short- to medium-range intrachromosomal
interactions [37]. Our analysis suggests that the machinery
for hypermutation has an outreach to other regions if these
regions are in spatial proximity in the interphase nucleus of
lymphoma cells.
Although the total number of HbP instances per sample
is higher in DLBCL and FL/DLBCL than in FL (Supple-
mentary Fig. S8M), when normalizing the number of HbP
instances to the square of the number of kataegis clusters
per sample (quadratic relationship between number of
Fig. 3 Hypermutation by proxy (HbP). A Genome-wide circos dia-
gram showing the positions of all kataegis clusters and their co-
occurrence by red arcs. The transparency of these arcs encodes the
recurrency of co-occurrence. Arcs are directed from the subject (i.e.,
primary target) to the object (i.e., secondary target) of the HbP rela-
tionship. B–D Detailed illustration of the HbP relationship between
S1PR2 and DNMT1. B Co-occurrence: black squares indicate in
which samples kataegis clusters are present. Annotation data shows
which subgroup the samples belong to, which cell of origin they have
and whether a SV is present (DEL_subjectObject: deletion involving
both subject (in this case S1PR2) and object (in this case DNMT1);
DEL_subject: deletion involving only the subject; TRA_BPsubject:
translocation with breakpoint in the subject; DUP_BPsubject: dupli-
cation with breakpoint in the subject). C Co-expression in the different
subgroups (and normal B cells, other B cells standing for naïve B
cells) and D tandem RNA chimeras as detected from RNA-seq: tracks
displaying from top to bottom: i) known transcripts of S1PR2 and
DNMT1; and Sashimi plots for transcriptomic data of ii) normal GC B
cells; iii) lymphoma samples with only S1PR2, i.e., the subject,
affected by kataegis; iv) lymphoma samples with both S1PR2 and
DNMT1, i.e., subject and object, affected by kataegis; v) lymphoma
samples with only DNMT1, i.e., the object, affected by kataegis; vi)
lymphoma samples with a deletion affecting either kataegis regions;
vii) lymphoma samples with a duplication affecting either kataegis
region; and viii) lymphoma samples affected by no event at all in this
genomic region. Vertical shading highlights the genomic positions of
the two kataegis regions. Numbers on arcs in the sashimi plots display
the mean number of splice events (spliced reads) found in the
corresponding group.
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kataegis foci and number of HbP instances, Supplementary
Fig. S8Q), FL showed higher values of this ratio (Supple-
mentary Fig. S8N).
New mutational signatures reflect mutagenic
mechanisms active in GC B cells
We investigated mutational signatures as traces of muta-
tional mechanisms active in tumors [27]. We used
2,133,341 somatic SNVs from 219 lymphomas from the
extended cohort defined above to perform a combination of
unsupervised and supervised analyses of mutational sig-
natures and found 14 different signatures (Fig. 4, Supple-
mentary Figs. S11, S12, Supplementary Table S9). Of
those, 11 (labeled “AC”) have been described before [27],
including four of six signatures previously identified in
gcBCL (Supplementary Table S9). Three new signatures
were discovered, termed L1, L2, and L3 (Fig. 4A, B). Two
of six mutational signatures from the original analysis of
gcBCL were not identified in this analysis: AC13 (linked to
the action of APOBEC enzymes) and AC5 (related to the
age of the patients at diagnosis, mechanism unknown).
Signature AC5 has high cosine similarity (see Methods) to
L1, L2, and AC9. Because of this high similarity, most
mutations we assign to L1 and L2 would have been
assigned to AC5, if AC5 was included and L1 and L2 were
not included in the analysis. Among the previously not
extracted signatures is AC3, which we detected in 21
lymphomas. Signature AC3 has been linked to defects in
homologous recombination repair (BRCAness) [38] which
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potentially confer synthetic lethality to poly(ADP-ribose)
polymerase inhibitors [39].
To relate B cell-specific mutational processes to the new
mutational signatures we compared all 14 signatures to the
AID target motif DGYW [40] and to our CSR and SHM
profiles by cosine similarity. L1 showed the highest simi-
larity to DGYW and to the CSR profile, while L2 showed
the highest similarity to the SHM profile. Signature L3 may
have some link to APOBEC enzyme activity. With
increasing factorization ranks in NMF, L3 splits apart from
AC2 (an APOBEC signature) at rank 7 (Supplementary Fig.
S11). Hence, the mutational mechanism causative for L3
remains presently unclear. In a complementary approach,
we compared the extracted mutational signatures to a syn-
thetic mutational signature based on data by Yaari et al.
[41], who extracted synonymous mutations from V and J
genes of the IGH locus from normal B cells in their 5-mer
sequence context to obtain the fingerprint of physiologic
SHM. We aggregated these into 3-mer context and used the
resulting triplet frequencies to derive a synthetic SHM
signature. Again, the newly identified signature L2 had
highest similarity to the synthetic SHM signature, providing
further evidence for SHM being the mechanism behind L2.
Several mutational processes show varying activity in
distinct genomic regions [42], and in particular for the B
cell-specific mechanisms a strong preference of certain
target regions is known [43]. We stratified SNVs according
to different genomic features and performed supervised
analysis of mutational signatures (Fig. 4C–E, Supplemen-
tary Table S10). First, to relate mutational signatures to the
physiological sites of B-cell mutagenesis, we checked for
enrichment and depletion patterns in the IG-VDJ genes and
the switch regions (Fig. 4C). L1 was enriched in the switch
regions while L2 was enriched in the VDJ regions, corro-
borating our previous assignment. Second, we related the
mutational signatures to chromatin states from normal GC B
cells (Fig. 4D). L1 was enriched in promoters, while L2 was
enriched in transcribed regions and enhancers as compared
to heterochromatic regions, consistent with previous
observations that B cell-specific mutagenesis primarily
affects active regions of the genome [44]. Third, we
assessed the influence of replication timing on exposure to
the mutational signatures (Fig. 4E, Supplementary Fig.
S10C). L1 showed a strong and L2 a moderate enrichment
in early replicating regions. Strikingly, AC9, which has
exclusively been found in B-cell malignancies and descri-
bed as being linked to SHM [27] shows an enrichment in
the heterochromatic, late replicating regions. In the IG loci,
AC9 is enriched in the constant, non-switch regions, further
corroborating that AC9 is not the fingerprint of SHM or
CSR. As expected, L1 and L2 were enriched in kataegis
clusters, with L1 being enriched in CSR-like and L2 in
SHM-like kataegis clusters as compared to the nonclustered
SNV stratum (Supplementary Fig. S12G). FLs had higher
contributions of L1, L2, and AC1 but lower contributions of
AC17, AC10, AC6, and AC2 as compared to DLBCLs
(Fig. 4F).
We propose that L1 and L2 are the mutational footprints
of CSR and SHM, respectively. The etiology of the B cell-
specific signature AC9 and the new signature L3 remain
enigmatic, though L3 may have some link to APOBEC
activity.
Fig. 4 New mutational signatures are partially linked to B-cell-
specifc mutagenic effects and exhibit characteristic enrichment
and depletion patterns. A Absolute exposures of the samples to the
mutational signatures extracted from the combined supervised and
unsupervised analyses of mutational signatures. Heights of the stacked
bar plots correspond to the number of SNVs explained by the
respective mutational signatures. Samples are ordered by subgroup and
then decreasing mutational load. For explanation of the identified
mutational signatures please refer to the main text. (B, insert) 96-
dimensional vectors of nucleotide exchange patterns in the triplet
context for the mutational signatures AC9, L1, L2 (all of which were
related to AID activity) and L3. Scales on the y-axes in the different
tracks are not fixed, instead a horizontal line is inserted at 5% for rough
orientation and comparison. C–H Enrichment and depletion patterns
of mutational signatures by stratified analyses along different stratifi-
cation axes, where different colors represent the different strata. C
Stratification by genomic regions in which the SNVs were located
(“none” = gray – outside of the IG loci, “IG_VDJ”= red – in VDJ
genes or intergenic regions between these, “IG_const_switch” = blue
– in the switch regions defined in this work, “IG_const_noSwitch” =
light blue – in the constant domain of IGH, but outside of the switch
regions). Signature L1 is enriched in the switch regions, L2 in the VDJ
regions. AC9 is enriched in the constant, non-switch regions (pKW=
2.2 × 10−11, pNem= 4.5 × 10−6). D Stratification by annotated GC B
cell-specific chromatin state. L1 was enriched in promoters (pKW=
1.2 × 10−15, pNem= 5.9 × 10−14), while L2 was enriched in transcribed
regions (pKW= 7.7 × 10−30, pNem= 4.7 × 10−14) and enhancers
(pNem= 1.4 × 10−8) as compared to heterochromatic regions. E Stra-
tification by replication timing, illustrating a rewiring of this measure:
L1 showed a strong (pKW= 2.7 × 10−19, pNem= 5.3 × 10−14, fold
change FC= 1.606) and L2 a moderate (pKW= 5.7 × 10−11, pNem=
5.6 × 10−6, FC= 1.347) enrichment in early replicating regions, as
opposed to AC9 which is enriched in late replicating regions (pKW=
6.3 × 10−51, pNem < 2 × 10
−16). RS: RepliSeq score. F Enrichment and
depletion patterns by subgroup of gcBCL: FLs had higher contribu-
tions of L1 (pKW= 4.74 × 10−3, pNem= 1.2 × 10−3), L2 (pKW= 6.51 ×
10−4, pNem= 1.7 × 10−4) and AC1 (pKW= 1.21 × 10−5, pNem= 1.3 ×
10−6) but lower contributions of AC17 (pKW= 2.02 × 10−3, pNem=
1.1 × 10−3), AC10 (pKW= 6.51 × 10−3, pNem= 2.1 × 10−4), AC6 (p=
2.05 × 10−2) and AC2 (pKW= 8.93 × 10−3, pNem= 1.3 × 10−2) as
compared to DLBCLs. G Stratification by consensus clustering of the
whole gcBCL cohort. While L3 (pKW= 9.78 × 10−3, enriched in the
SOCS1-like, B2M-like and TP53-like consensus clusters), AC1 (pKW
= 9.78 × 10−3, enriched in the CSMD1-like and BCL2-like consensus
clusters) and AC2 (pKW= 4.88 × 10−2, depleted in the BCL2-like
cluster) were significantly enriched or depleted between the consensus
clusters, L1 (high in the PIM1-like, BCL2-like and MYD88-like
consensus clusters) and L2 (high in the B2M-like, BCL2-like and
CSMD1-like consensus clusters) only showed trends. H Stratification
by consensus clustering of only the DLBCL subgroup. After correct-
ing for multiple testing, no significant effect was observed, with trends
for L3 (high in TP53-like) and AC1 (high in BCL2-like). Error bars in
C–H display standard error of the mean (SEM).
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Mutational mechanisms during lymphoma
evolution
To dissect the activity of the different mutational processes
during B-cell lymphoma evolution, we stratified SNVs
according to their cancer cell fractions (CCFs), i.e., the
fraction of tumor cells harboring the respective variant. A
high CCF identifies mutations which arose in the precursor
cell or early in tumor evolution, while a low CCF is char-
acteristic for mutations which arose late in tumor evolution
(see Methods). Stratified analysis of mutational signatures
showed an enrichment of AC1 (spontaneous deamination)
and AC2 (APOBEC) in early clonal evolution (Supple-
mentary Fig. S12D). Among the mutational signatures
related to B cell-specific mutational processes, L1 showed a
trend towards enrichment in early and AC9 in late clonal
evolution. No enrichment was observed for L2. Following
the hypothesis that the absence of enrichment patterns for
L2 might indicate ongoing SHM activity in gcBCL, we
investigated the distribution of CCFs in the IG loci. SNVs
in the constant part of IGH were significantly earlier and
SNVs in the variable parts of the IG loci were significantly
later in clonal evolution than SNVs outside of the IG loci
(Supplementary Fig. S12B). Hence, SHM in the variable
parts of the IG loci is ongoing in gcBCL, while CSR
appears to happen mostly before clonal expansion, in
agreement with the genome-wide enrichment patterns for
L1 (CSR) and L2 (SHM).
Drivers of gcBCL
Only roughly 1% of somatic mutations were in protein
coding sequences, with a median of 88 coding variants per
sample (range 11–974, subgroup specific median DLBCL:
114, FL: 59.5, FL/DLBCL: 128; Supplementary Fig. S1,
Supplementary Table S3). After integrating all types of
variants with coding potential, we observed high mutational
recurrence in known gcBCL drivers like KMT2D, CREBBP,
BCL2, TNFRSF14, PIM1, SOCS1, and CDKN2A (Fig. 5,
Supplementary Figs. S13, S14; see Supplementary Infor-
mation for recurrently mutated noncoding genes). To dif-
ferentiate between passenger and driver mutations and to
identify subgroup-specific low recurrence drivers we
applied IntOGen [45] to the whole cohort and to FL and
DLBCL separately. We identified 118 driver genes in the
179 gcBCL with matched normal control (Supplementary
Table S11), of which 9 and 8 were not significant in FLs
(ADAMTS1, ANKRD12, DHX16, DNM2, LRP12, SIAH2,
SIN3A, ZNF217, ZNF292) and not significant in DLBCLs
(BCL2, CDC42BPB, CXCR4, DHX15, JUP, MGEA5,
MYCBP2, PDS5B), respectively.
Encouraged by recent studies proposing genomic clas-
sifications of DLBCL based on data from whole exome
sequencing [4–6] we applied NMF as a soft clustering
technique on binarized data of driver gene alterations, both
to the subset of DLBCL in our cohort (initially 76 cases,
but 72 after excluding four hypermutated cases, defined by
mutational load more than two standard deviations above
mean SNV mutational load), and to the whole cohort. As
described in the Supplementary Information and shown in
Supplementary Fig. S15 this yielded consensus clusters
comparable to the prior studies, which supports the validity
of our approach for driver gene identification from the
whole genome sequences. Notably, when we extended the
approach from DLBCL to the full cohort (again excluding
the four hypermutated DLBCLs), the optimal number of
consensus clusters was nine, thereby revealing a more
detailed substructure of gcBCL entities than in the pub-
lished studies (Supplementary Fig. S16). We furthermore
investigated congruence and cross-over of the DLBCL
cases between the consensus clusters extracted only among
the DLBCLs (Supplementary Fig. S15) and those con-
sensus clusters extracted among all gcBCL cases (Supple-
mentary Fig. S16), showing that the majority of cases in the
MYD88-like and TP53-like DLBCL-only consensus clus-
ters also mapped to the respective gcBCL consensus
clusters, whereas cases from the BCL2-like DLBCL-only
consensus cluster also populated the CSMD1-like gcBCL
consensus cluster and cases from the BCL6-like DLBCL-
only consensus cluster also populated the PIM1-like
gcBCL consensus cluster. Numbers are displayed in Sup-
plementary Table S12C. We then took these consensus
clusters and investigated enrichment and depletion patterns
of the mutational signatures identified in our analysis
(Fig. 4G, H). L3 was enriched in the SOCS1-like, B2M-
like and TP53-like consensus clusters, AC1 was enriched
in the CSMD1-like and BCL2-like consensus clusters, AC2
was depleted in the BCL2-like cluster, L1 showed a trend
and was higher in the PIM1-like, BCL2-like and MYD88-
like consensus clusters compared to background, and
L2 showed a trend and was higher in the B2M-like, BCL2-
like, and CSMD1-like consensus clusters compared to
background (Fig. 4G). Stratification by consensus cluster-
ing of only the DLBCL subgroup (Fig. 4H) revealed
only trends for L3 (high in TP53-like) and AC1 (high in
BCL2-like).
We sought to identify the mechanisms mutating the
driver genes as well as other recurrently mutated genes. To
assess the contribution of B cell-specific hypermutation, we
mapped kataegis clusters to driver genes and found that
57.1% of the driver or recurrently mutated genes showed
indications for kataegis in at least one case (36.4% when
restricting the analysis to coding mutations, Supplementary
Table S13). Complementarily, 42.9% of the driver and re-
currently mutated genes were depleted in mutations affect-
ing the DGC/CGH motif, indicating non-AID-mediated
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mutagenesis (Fig. 5, Supplementary Fig. S14). While genes
that were recurrently affected by kataegis generally showed
an enrichment of SNVs in the DGC motif, the reverse
relation was often not fulfilled, suggesting that several
genes are recurrently targeted by AID-mediated, but non-
clustered mutations.
Fig. 5 B cell-specific mutagenesis alone is not sufficient to drive
lymphomagenesis. Oncoprint of coding (upper part of the figure) and
noncoding (lower fifth of the figure dominated by blue color) muta-
tions. The x-coordinate encodes samples which are pre-sorted by
subgroups. The y-coordinate encodes different genes or non-coding
genes. Different mutation types are encoded by the fill color of the
fields in the oncoprint, where different types of mutation can coexist in
one sample. Four layers of annotation on the right side of the oncoprint
display (i) whether a gene is identified as a driver and (ii) how strongly
mutations in AID-specific motifs are enriched, (iii) the best matching
signature, and (iv) replication timing.
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Next we compared cohort-wide mutational profiles for
each driver and recurrently mutated gene with the pre-
viously identified mutational signatures using cosine simi-
larity. 37.7% of the driver genes exhibited a profile most
similar to signature L1 and 18.2% to L2, while 15.6% were
most similar to AC9 (Fig. 5). Several drivers showed no
evidence for B cell-specific mutagenesis, i.e., no enrichment
for the AID target motif, no kataegis, and no predominant
mutagenesis by a B cell-specific signature. Examples are
TP53 and CARD11 with a pattern of SNVs dominated by
signatures AC1 and AC6 (associated with defects in DNA
mismatch repair).
Finally, we investigated the timing of coding driver
mutations in the course of lymphoma evolution. We
determined the median CCF per driver gene and ranked the
genes accordingly to classify driver genes as early or late
(Supplementary Fig. S17). In agreement with our previous
analyses, early drivers were predominantly mutated by L1,
whereas for intermediate and late drivers L2 and AC9 were
the dominating signatures. Genes affecting NFκB signaling
(PPP4C, NFKBIE, NFKBIA) [46–48] were mutated
early during clonal evolution, suggesting that activation of
NFκB signaling is essential for initiation of B-cell
lymphomagenesis.
Discussion
Most B-cell lymphomas derive from GC B cells [15].
Considering that most newly generated B cells will never
participate in a GC reaction during their lifetime, and that
those which do will be GC B cells only for a short time of
about three weeks [49], and then continue to live as
memory B cells or plasma cells for years or decades in
humans, it becomes evident that the GC is a highly dan-
gerous place for B cells. Key factors that contribute to the
risky life of GC B cells are (i) the very high proliferation
rate of GC B cells [50], which increases the risk for DNA
replication-associated genetic lesions and may prepare the
cells for continuous proliferation as transformed cells, (ii)
the generation of chromosomal translocations as mistakes
of SHM and CSR [16], (iii) off-target mutation activity of
SHM [13, 14], and iv) a dampened DNA repair activity
needed to tolerate the genotoxic stress imposed on GC B
cells by their fast proliferation and SHM activity [51].
Moreover, B cells can repeatedly undergo GC reactions,
and this repeated exposure to the mutagenic GC micro-
environment may indeed play a role in FL pathogenesis
[52]. However, a comprehensive understanding of the
mutagenic mechanisms causing the malignant transfor-
mation of GC B cells is still missing. By analyzing a large
number of prototypical gcBCL for mutations not only in
the coding but also the noncoding genome we were in a
position to study mutational mechanisms in gcBCL at
unprecedented depth.
One of the major findings from our study is that besides
kataegis regions of very high mutational density, the
lymphomas also show recurrent regions of psichales with
an intermediate mutation density. The observation that
kataegis regions mostly affect early replicating genomic
regions, while psichales focusses on late replicating
regions, points to the involvement of distinct mutational
mechanisms. Indeed, the distinct mutation patterns in
kataegis and psichales clusters suggest a major role of off-
target AID activity for kataegis, and of diminished DNA
repair activity in late replicating regions of psichales
clusters. The GC-dependency of kateagis regions is sup-
ported by a recent study published during the review
process of this paper which reported that IGHV gene
unmutated chronic lymphocytic leukemias lack kataegis
regions outside the IGH switch regions [53]. The increased
mutation density in late replicating regions is not B cell-
specific and known from other types of cancer [25, 29]. A
second novel mutation feature that we uncovered is
hypermutation by proxy. This describes the surprising
observation that some kataegis clusters generated by
strong hypermutation activity can apparently promote
hypermutation in other loci if co-localized in the nucleus.
Hence, accumulation of hypermutation complexes on
particular genomic regions apparently poses the risk to
also mutagenize spatially closely localized chromosomal
regions in trans. This concept is supported by a recent
lymphoma cell line study showing hot spots for SHM in
topologically associated chromatin domains, although that
study lacked the aspect of directionality that we revealed
[54]. Third, while prior studies on off-target AID activity
only considered off-target SHM [13], we revealed that also
the mutation machinery involved in CSR apparently has
off-target mutation activity beyond inducing translocations
and contributes to the SNV burden of gcBCL. Please note
that the two AID-associated signatures we describe here
are distinct from the canonical and noncanonical AID
signatures reported previously [27, 55, 56]. Whereas the
canonical AID signature is a general AID signature based
on the AID hotspot motif, not distinguishing SHM and
CSR machinery associated mutagenesis, the noncanoncial
AID signature (signature 9 in ref. [27]) is indeed primarily
linked to polymerase eta mutagenesis, and not AID
directly [27, 55, 56]. Fourth, overall, about half of the
gcBCL driver genes show signs of targeting by B cell-
specific mutational processes, and the resulting mutations
likely play a major pathogenetic role both in the initiation
of lymphomagenesis and in the generation of intratumoral
heterogeneity. Fifth, using NMF consensus clustering
on data integrating various mutation types across the dif-
ferent gcBCLs, we identified nine consensus clusters
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corresponding to genomic subtypes. In conclusion, the
development of gcBCL is much more complex than pre-
viously appreciated and gcBCL are unique among human
cancers in the extent and diversity of how cell-type-
specific processes contribute to mutations, localized
hypermutation and malignant transformation.
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